Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Aβ

American Journal of Pathology

Volumn 175, Issue 1, 2009, Pages 262-270

  Palmer, Jennifer C ^a   Baig, Shabnam ^a   Kehoe, Patrick G ^a   Love, Seth ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; ANTIBODY; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME 2; ENDOTHELIN RECEPTOR ANTAGONIST; MESSENGER RNA; MONOMER; NERVE PROTEIN; OLIGOMER; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MULTIINFARCT DEMENTIA; NEOCORTEX; NERVOUS TISSUE; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TEMPORAL CORTEX; UPREGULATION;

EID: 67649984550     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.081054     Document Type: Article

References (57)

1. Tanzi RE, Bertram L: Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005, 120:545-555
2. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yao RQ, Beach T, Sue L, Sabbagh M, Cai HB, Wong P, Price D, Shen Y: Amyloid-β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA 2004, 101:3632-3637
3. Yang LB, Lindholm K, Yan RQ, Citron M, Xia WM, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y: Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 2003, 9:3-4
4. Preston SD, Steart PV, Wilkinson A, Nicoll JAR, Weller RO: Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid-β from the human brain. Neuropathol Appl Neurobiol 2003, 29:106-117
5. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE: Cerebral amyloid angiopathy - Amyloid-β accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998, 153:725-733
6. Lam FC, Liu RH, Lu PH, Shapiro AB, Renoir JM, Sharom FJ, Reiner PB: β-Amyloid efflux mediated by p-glycoprotein. J Neurochem 2001, 76:1121-1128
7. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV: Clearance of Alzheimer's amyloid-β(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000, 106:1489-1499
8. Eckman EA, Eckman CB: Aβ-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 2005, 33:1101-1105
9. Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu J, Zhou H, Atchison K, Wagner E, Zaleska MM, Das I, Arias RL, Bard J, Riddell D, Gardell SJ, Abou-Gharbia M, Robichaud A, Magolda R, Vlasuk GP, Bjornsson T, Reinhart PH, Pangalos MN: Enhanced clearance of Aβin brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci USA 2008, 105:8754-8759
10. Jiang Q, Lee CYD, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE: ApoE promotes the proteolytic degradation of Aβ. Neuron 2008, 58: 681-693
11. Hoang MV, Turner AJ: Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin. Biochem J 1997, 327:23-26
12. Johnson GD, Stevenson T, Ahn KH: Hydrolysis of peptide hormones by endothelin-converting enzyme-1-A comparison with neprilysin. J Biol Chem 1999, 274:4053-4058
13. Eckman EA, Reed DK, Eckman CB: Degradation of the Alzheimer's amyloid-β peptide by endothelin-converting enzyme. J Biol Chem 2001, 276:24540-24548
14. Emoto N, Yanagisawa M: Endothelin-converting enzyme-2 is a membrane-bound. Phosphoramidon-sensitive metalloprotease with acidic Ph optimum. J Biol Chem 1995, 270:152620-15268
15. Davenport AP, Kuc RE: Cellular expression of isoforms of endothelinconverting enzyme-1 (ECE-1c, ECE-1b, and ECE-1a) and endothelinconverting enzyme-2. J Cardiovasc Pharmacol 2000, 36:S12-S14
16. Mzhavia N, Pan H, Che FY, Fricker LD, Devi LA: Characterization of endothelin-converting enzyme-2 - Implication for a role in the nonclassical processing of regulatory peptides. J Biol Chem 2003, 278:14704-14711
17. Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC, Takeda S, Clouthier DE, Yanagisawa M: Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest 2000, 105:1373-1382
18. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB: Alzheimer's disease β-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 2003, 278:2081-2084
19. Rodriguiz RM, Gadnidze K, Ragnauth A, Dorr N, Yanagisawa M, Wetsel WC, Devi LA: Animals lacking endothelin-converting enzyme-2 are deficient in learning and memory. Genes Brain Behav 2008, 7:418-426
20. Weeraratna AT, Kalehua A, DeLeon I, Bertak D, Maher G, Wade MS, Lustig A, Becker KG, Wood W, Walker DG, Beach TG, Taub DD: Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissues. Exp Cell Res 2007, 313: 450-461
21. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991, 82:239-259
22. (-∇∇CT) Method. Methods (Duluth) 2001, 25:402-408
23. van Helmond Z, Heesom K, Love S: Characterisation of two antibodies to oligomeric Aβ and their use in ELISAs on human brain tissue homogenates. J Neurosci Methods 2009, 176:206-212
24. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S: Aβ-degrading enzymes in Alzheimer's disease. Brain Pathol 2008, 18:240-252
25. Akiyama H, Kondo H, Ikeda K, Kato M, McGeer PL: Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid β-protein (Aβ) deposition. Brain Res 2001, 902:277-281
26. Carpentier M, Robitaille Y, DesGroseillers L, Boileau G, Marcinkiewicz M: Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2002, 61:849-856
27. Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG: Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2006, 65:1012-1021
28. Yasojima K, Akiyama H, McGeer EG, McGeer PL: Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide. Neurosci Lett 2001, 297:97-100
29. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, Schellenberg GD, Jin LW, Kovacina KS, Craft S: Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon 4 allele. Am J Pathol 2003, 162:313-319
30. Perez A, Morelli L, Cresto JC, Castano EM: Degradation of soluble amyloid β-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res 2000, 25:247-255
31. Zhao Z, Xiang ZM, Haroutunian V, Buxbaum JD, Stetka B, Pasinetti GM: Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol Aging 2007, 28:824-830
32. Wang DS, Lipton RB, Katz MJ, Davies P, Buschke H, Kuslansky G, Verghese J, Younkin SG, Eckman C, Dickson DW: Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J Neuropathol Exp Neurol 2005, 64:378-385
33. Hellstrom-Lindahl E, Ravid R, Nordberg A: Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with Aβ levels. Neurobiol Aging 2008, 29:210-221
34. Russo R, Borghi R, Markesbery W, Tabaton M, Piccini A: Neprylisin decreases uniformly in Alzheimer's disease and in normal aging. FEBS Lett 2005, 579:6027-6030
35. Vepsalainen S, Hiltunen M, Helisalmi S, Wang J, van Groen T, Tanila H, Soininen H: Increased expression of Aβ degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology. Neurosci Lett 2008, 438:216-220
36. Leal MC, Dorfman VB, Gamba AF, Frangione B, Wisniewski T, Castano EM, Sigurdsson EM, Morelli L: Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic Tg2576 mice with Alzheimer pathology. J Neuropathol Exp Neurol 2006, 65:976-987
37. Apelt J, Ach K, Schliebs R: Aging-related down-regulation of neprilysin, a putative β-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of β-amyloid plaques. Neurosci Lett 2003, 339:183-186
38. Deb S, Zhang JWJ, Gottschall PE: Activated isoforms of MMP-2 are induced in U87 human glioma cells in response to β-amyloid peptide. J Neurosci Res 1999, 55:44-53
39. Jung SS, Zhang WB, Van Nostrand WE: Pathogenic Aβ induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells. J Neurochem 2003, 85: 1208-1215
40. Lee JM, Yin KJ, Hsin I, Chen SW, Fryer JD, Holtzman DM, Hsu CY, Xu J: Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy. Ann Neurol 2003, 54:379-382
41. Tucker HM, Kihiko-Ehmann M, Wright S, Rydel RE, Estus S: Tissue plasminogen activator requires plasminogen to modulate amyloid-β neurotoxicity and deposition. J Neurochem 2000, 75:2172-2177
42. Niwa K, Carlson GA, Iadecola C: Exogenous Aβ 1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab 2000, 20: 1659-1668
43. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C: Aβ-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol-Heart Circul Physiol 2001, 281:H2417-H2424
44. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M: β- Amyloidmediated vasoactivity and vascular endothelial damage. Nature 1996, 380:168-171
45. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C: Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 2002, 9:61-68
46. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C: Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol-Heart Circ Physiol 2002, 283:H315-H323
47. Kalaria RN: Cerebral vessels in ageing and Alzheimer's disease. Pharmacol Ther 1996, 72:193-214
48. Jagust WJ: Neuroimaging in dementia. Neurol Clin 2000, 18:885-901
49. Dekosky ST, Shih WJ, Schmitt FA, Coupal J, Kirkpatrick C: Assessing utility of single photon emission computed tomography Spect Scan in Alzheimer Disease correlation with cognitive severity. Alzheimer Dis Assoc Disord 1990, 4:14-23
50. Imran MB, Kawashima R, Awata S, Sato K, Kinomura S, Ono S, Sato M, Fukuda H: Tc-99m HMPAO SPECT in the evaluation of Alzheimer's disease: correlation between neuropsychiatric evaluation and CBF images. J Neurol Neurosurg Psych 1999, 66:228-232
51. Shiraishi H, Chang CC, Kanno H, Yamamoto I: The relationship between cerebral blood flow and cognitive function in patients with brain insult of various etiology. J Clin Neurosci 2004, 11:138-141
52. Shah R: Endothelins in health and disease. Eur J Int Med 2007, 18:272-282
53. Wright CE, Fozard JR: Regional vasodilation is a prominent feature of the haemodynamic response to endothelin in anaesthetized, spontaneously hypertensive rats. Eur J Pharmacol 1988, 155:201-203
54. Haynes WG, Ferro CJ, O'Kane KP, Somerville D, Lomax CC, Webb DJ: Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996, 93:1860-1870
55. Haynes WG, Webb DJ: Contribution of endogenous generation of endothelin-1 to basal vascular tone.[see comment]. Lancet 1994, 344:852-854
56. Ehrenreich H, Schilling L: New developments in the understanding of cerebral vasoregulation and vasospasm - the Endothelin Nitric-Oxide Network. Cleve Clin J Med 1995, 62:105-116
57. Crawford F, Suo ZM, Fang CH, Mullan M: Characteristics of the in vitro vasoactivity of β-amyloid peptides. Exp Neurol 1998, 150:159-168